Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in the registration statement on Form F-1 (File No. 333 -193792), initially filed with the Securities and Exchange Commission, or the SEC, on February 6, 2014 and declared effective by the SEC on March 12, 2014, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update any forward-looking statements.

 GALMED PHARMACEUTICALS LTD.Condensed Consolidated Balance SheetsU.S. Dollars in thousands, except share data and per share dataSuccessorPredecessorAs of
June 30, 2014As of
December 31,
2013UnauditedAuditedAssetsCurrent AssetsCash and cash equivalents$
37,399

$
37
Other accounts receivable61

16Total current assets37,640

153Property and equipment, net24

13Total assets$
37,484'/>"/>

SOURCE Galmed Pharmaceuticals Ltd.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... of benzene. Benzene is processed to get such derivatives as ethylbenzene, a precursor ... are principally used within the automotive industry for the production of tyres and ...
(Date:8/3/2015)... ... , ... Nine field days to promote practices that improve soil health will ... Health Partnership , the field days will demonstrate how changing certain practices, such as ... income. , Brent Bible has practiced no-till farming and planted cover crops on his ...
(Date:8/3/2015)... DOVER, Delaware , August 3, 2015 ... engaged in the commercialization of its Bio-electrical Signal Therapy ... the noninvasive treatment of hard to heal chronic wounds, ... distribution agreement with Chemipal, an Israeli distributor specializing in ... BST device. Chemipal is a 70 years ...
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
Breaking Biology Technology:World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3Soil Health Field Days Kick Off Throughout Midwest 2Soil Health Field Days Kick Off Throughout Midwest 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4
... Research,Institute (BBRI) in Watertown, Massachusetts, was once again ... by Moody,s Investor Services, affirming,the Institute,s financial stability ... overall precarious economy that have left some similar,organizations ... confirmation,of our financial health," says BBRI Director and ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... conference call on Monday, March 31, 2008 at 9:00 ... ended December 31, 2007 financial,results and provide an update ... call, please dial 1-877-407-4018 (USA) or,1-201- 689-8471 (international). A ...
... Inc. (OTC Bulletin Board: WGBS), a leading ... and stem cell,research systems, today announced the ... company,s SmartSlide(TM) Micro-Incubation System with,Labtech International Limited ... in,France. The distributor agreement covers WaferGen,s entire ...
Cached Biology Technology:Boston Biomedical Research Institute Maintains Baa3 Rating from Moody's 2Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 4WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 5
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... When a portion of a zebrafish's heart is removed, ... that forms in the wound and the protective cell ... functional new heart tissue, Duke University Medical Center scientists ... growth factors facilitate the interaction between the cell mass ...
... the Gladstone Institute of Virology and Immunology (GIVI) have identified ... acts against HIV, a finding that may lead to new ... published today, Oct. 2, 2006, in Proceedings of the National ... in the laboratory of GIVI Director Warner C. Greene, MD, ...
... high tech tools, researchers have identified three proteins that ... 20 months before the rejection occurred. , Lung transplant ... about 45% over five years, said lead investigator and ... to predict which transplants will fail, and when signs ...
Cached Biology News:Key to zebrafish heart regeneration uncovered 2Key to zebrafish heart regeneration uncovered 3Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... buffered anti-freeze environment for enzyme conjugated antibodies ... low viscosity solution at -20C , ... sampling is convenient , Contains preservatives ... Protect enzyme conjugates during storage without ...
Biology Products: